Here is the design of a clinical trial:

Official Title: Prevention of Persistent Pain With LidocAine iNfusions in Breast Cancer Surgery (PLAN)

Included conditions:
- Post-mastectomy Pain Syndrome
- Breast Cancer
- Pain, Postoperative
- Pain, Chronic

Study Armgroups:
- {'label': 'Intervention', 'type': 'EXPERIMENTAL', 'description': 'Intraoperative intravenous lidocaine/placebo infusion', 'interventionNames': ['Drug: Lidocaine 20mg/ml']}
- {'label': 'Control', 'type': 'PLACEBO_COMPARATOR', 'description': 'Intraoperative intravenous lidocaine/placebo infusion', 'interventionNames': ['Drug: Placebo']}

Interventions:
- {'type': 'DRUG', 'name': 'Lidocaine 20mg/ml', 'description': 'Patients in the intervention group will receive an IV lidocaine infusion using a dosage regimen of 1.5 mg/kg bolus of a 2% lidocaine solution with induction of general anesthesia followed by a 2.0 mg/kg/hour infusion until the end of surgery (and up to 30 minutes into recovery room).', 'armGroupLabels': ['Intervention'], 'otherNames': ['Lidocaine 2%']}
- {'type': 'DRUG', 'name': 'Placebo', 'description': 'Patients in the control group will receive a placebo bolus and infusion with normal saline (0.9% sodium chloride solution) until the end of surgery (and up to 30 minutes into recovery room).', 'armGroupLabels': ['Control'], 'otherNames': ['0.9% sodium chloride solution']}

Primary Outcomes:
- {'measure': 'Development of persistent pain 3-months after breast cancer surgery', 'description': 'Persistent pain at 3-months', 'timeFrame': '3- months'}

Please estimate the sample size based on the assumption: 
The trial aims for 90% power to detect the effect with a two-sided significance level (α) of 0.05 and accounts for a 10% loss-to-follow-up rate.
Sample size
        Only a few prospective studies provide data on the prevalence of persistent pain at 3Â months after breast cancer surgery, with estimates ranging from 33 to 82% [32, 34, 49, 73, 74]. The largest study (nâ=â150) reported a 33% prevalence at 3 months; however, only 84 (56%) patients provided follow-up data. Our pilot (nâ=â100), conducted at two Canadian centers, found a prevalence of persistent pain of 58.3% (95% CI 38.6 to 78.1%) in the control group at 3 months. Furthermore, our pilot found a 32% relative risk reduction (RRR) with the use of IV lidocaine, whereas Grigoras et al. [32] and Kim et al. [34] found a 75 and a 50% RRR at 3 months, respectively. We believe these RRR estimates are likely overestimations of the true treatment effect given the small size of the trials, the multiple pathogenic mechanisms involved, and the rarity of such large effect sizes in the medical literature [75, 76] and within chronic pain prevention trials [77].
        We have therefore chosen to design our trial to identify a plausible, but clinically important, 25% RRR while using 30% as the control group pain prevalence at 3 months. To achieve 90% power to detect in a two-sided comparison with Î±â=â0.05, and 10% loss-to follow-up, we will need a sample of 1602 participants. For a fixed RRR, power increases as the control group prevalence increases. This sample size also provides adequate power to inform realistic RRRs in important but less common secondary outcomes such as presence of moderate-to-severe pain. For example, based on a control group prevalence of moderate-to-severe pain of 16% in our pilot, we have 80% power to detect a RRR of 31% or greater.